PRELUDE CAPITAL MANAGEMENT, LLC - JOUNCE THERAPEUTICS INC ownership

JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 84 filers reported holding JOUNCE THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.5%.

Quarter-by-quarter ownership
PRELUDE CAPITAL MANAGEMENT, LLC ownership history of JOUNCE THERAPEUTICS INC
ValueSharesWeighting
Q1 2022$100,000
-6.5%
14,800
+15.6%
0.00%0.0%
Q4 2021$107,000
+37.2%
12,800
+12.3%
0.00%
+50.0%
Q2 2021$78,000
+3800.0%
11,400
+5600.0%
0.00%
Q3 2020$2,000
-94.7%
200
-95.3%
0.00%
-100.0%
Q4 2019$38,000
+81.0%
4,300
+30.6%
0.00%0.0%
Q3 2018$21,000
+16.7%
3,293
+43.2%
0.00%0.0%
Q2 2018$18,0002,3000.00%
Other shareholders
JOUNCE THERAPEUTICS INC shareholders Q4 2018
NameSharesValueWeighting ↓
Pharmstandard International S.A. 662,063$10,315,00030.07%
Omega Fund Management, LLC 579,650$9,031,0005.11%
Casdin Capital, LLC 399,825$6,229,0001.76%
Cormorant Asset Management, LP 359,738$5,605,0000.99%
Foresite Capital Management II, LLC 119,912$1,868,0000.76%
Redmile Group, LLC 955,598$14,888,0000.73%
PFM Health Sciences, LP 1,727,997$26,922,0000.53%
Fosun International Ltd 285,960$4,455,0000.44%
Partner Investment Management, L.P. 14,265$222,0000.21%
Spark Investment Management LLC 162,200$2,527,0000.14%
View complete list of JOUNCE THERAPEUTICS INC shareholders